STIM / Neuronetics: An Overdue Checkup

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. more_horizontal

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith S more_horizontal

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sul more_horizontal

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical techn more_horizontal

Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM). more_horizontal

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hol more_horizontal

MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, more_horizontal

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, h more_horizontal